The New 5F9 Antibody Looks Encouraging as it Targets MDS and AML Leukemia in a Phase 1b Clinical Trial

  The California Institute for Regenerative Medicine (CIRM) has funded a study by a company called Forty Seven, Inc. The clinical trial is investigating the benefits of a drug therapy for two cancers…

Continue Reading The New 5F9 Antibody Looks Encouraging as it Targets MDS and AML Leukemia in a Phase 1b Clinical Trial
Experimental Neurofibromatosis Type 1 Therapy Earns Fast Track Designation
qimono / Pixabay

Experimental Neurofibromatosis Type 1 Therapy Earns Fast Track Designation

According to a story from Global Genes, the drug developer SpringWorks Therapeutics announced that the US Food and Drug Administration (FDA) has granted the company Fast Track Designation for its…

Continue Reading Experimental Neurofibromatosis Type 1 Therapy Earns Fast Track Designation

Scholarships are Available for the 2019 International Pain Summit Which Will be Held in LA this November

IPain The International Pain Foundation (IPain) is a nonprofit organization dedicated to supporting those with chronic pain due to neurological, musculoskeletal, inflammatory, degenerative, and emotional conditions. They aim to improve…

Continue Reading Scholarships are Available for the 2019 International Pain Summit Which Will be Held in LA this November
New Partnership Aims to Develop New Mobility Controls for Amyotrophic Lateral Sclerosis Patients
source: pixabay.com

New Partnership Aims to Develop New Mobility Controls for Amyotrophic Lateral Sclerosis Patients

According to a story from ucf.edu, a new partnership between Mayo Clinic and Limbitless Solutions is planning initiate a new clinical trial that aims to improve mobility options for patients…

Continue Reading New Partnership Aims to Develop New Mobility Controls for Amyotrophic Lateral Sclerosis Patients
Close Menu